Skip to main content
bioRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search
New Results

SARS-CoV-2 variants B.1.351 and B.1.1.248: Escape from therapeutic antibodies and antibodies induced by infection and vaccination

View ORCID ProfileMarkus Hoffmann, Prerna Arora, Rüdiger Groß, Alina Seidel, Bojan Hörnich, Alexander Hahn, Nadine Krüger, Luise Graichen, Heike Hofmann-Winkler, Amy Kempf, Martin Sebastian Winkler, Sebastian Schulz, Hans-Martin Jäck, Bernd Jahrsdörfer, Hubert Schrezenmeier, Martin Müller, Alexander Kleger, Jan Münch, View ORCID ProfileStefan Pöhlmann
doi: https://doi.org/10.1101/2021.02.11.430787
Markus Hoffmann
1Infection Biology Unit, German Primate Center, Göttingen, Germany
2Faculty of Biology and Psychology, Georg-August-University Göttingen, Göttingen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Markus Hoffmann
  • For correspondence: mhoffmann@dpz.eu spoehlmann@dpz.eu
Prerna Arora
1Infection Biology Unit, German Primate Center, Göttingen, Germany
2Faculty of Biology and Psychology, Georg-August-University Göttingen, Göttingen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rüdiger Groß
3Institute of Molecular Virology, Ulm University Medical Center, Ulm, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alina Seidel
3Institute of Molecular Virology, Ulm University Medical Center, Ulm, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bojan Hörnich
4Junior Research Group Herpesviruses - Infection Biology Unit, German Primate Center, Göttingen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexander Hahn
4Junior Research Group Herpesviruses - Infection Biology Unit, German Primate Center, Göttingen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nadine Krüger
1Infection Biology Unit, German Primate Center, Göttingen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luise Graichen
1Infection Biology Unit, German Primate Center, Göttingen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Heike Hofmann-Winkler
1Infection Biology Unit, German Primate Center, Göttingen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amy Kempf
1Infection Biology Unit, German Primate Center, Göttingen, Germany
2Faculty of Biology and Psychology, Georg-August-University Göttingen, Göttingen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin Sebastian Winkler
5Department of Anaesthesiology, University of Göttingen Medical Center, Göttingen, Georg-August University of Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sebastian Schulz
6Division of Molecular Immunology, Department of Internal Medicine 3, Friedrich-Alexander University of Erlangen-Nürnberg, Erlangen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hans-Martin Jäck
6Division of Molecular Immunology, Department of Internal Medicine 3, Friedrich-Alexander University of Erlangen-Nürnberg, Erlangen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bernd Jahrsdörfer
7Department of Transfusion Medicine, Ulm University, Ulm, Germany and Institute for Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service Baden-Württemberg – Hessen and University Hospital Ulm, Ulm, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hubert Schrezenmeier
7Department of Transfusion Medicine, Ulm University, Ulm, Germany and Institute for Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service Baden-Württemberg – Hessen and University Hospital Ulm, Ulm, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin Müller
8Department of Internal Medicine 1, Ulm University Hospital, Ulm, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexander Kleger
8Department of Internal Medicine 1, Ulm University Hospital, Ulm, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jan Münch
3Institute of Molecular Virology, Ulm University Medical Center, Ulm, Germany
9Core Facility Functional Peptidomics, Ulm University Medical Center, Ulm, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stefan Pöhlmann
1Infection Biology Unit, German Primate Center, Göttingen, Germany
2Faculty of Biology and Psychology, Georg-August-University Göttingen, Göttingen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Stefan Pöhlmann
  • For correspondence: mhoffmann@dpz.eu spoehlmann@dpz.eu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Preview PDF
Loading

SUMMARY

The global spread of SARS-CoV-2/COVID-19 is devastating health systems and economies worldwide. Recombinant or vaccine-induced neutralizing antibodies are used to combat the COVID-19 pandemic. However, recently emerged SARS-CoV-2 variants B.1.1.7 (UK), B.1.351 (South Africa) and B.1.1.248 (Brazil) harbor mutations in the viral spike (S) protein that may alter virus-host cell interactions and confer resistance to inhibitors and antibodies. Here, using pseudoparticles, we show that entry of UK, South Africa and Brazil variant into human cells is susceptible to blockade by entry inhibitors. In contrast, entry of the South Africa and Brazil variant was partially (Casirivimab) or fully (Bamlanivimab) resistant to antibodies used for COVID-19 treatment and was less efficiently inhibited by serum/plasma from convalescent or BNT162b2 vaccinated individuals. These results suggest that SARS-CoV-2 may escape antibody responses, which has important implications for efforts to contain the pandemic.

Competing Interest Statement

The authors have declared no competing interest.

Footnotes

  • ↵11 Lead contact

Copyright 
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted February 11, 2021.
Download PDF
Email

Thank you for your interest in spreading the word about bioRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
SARS-CoV-2 variants B.1.351 and B.1.1.248: Escape from therapeutic antibodies and antibodies induced by infection and vaccination
(Your Name) has forwarded a page to you from bioRxiv
(Your Name) thought you would like to see this page from the bioRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
SARS-CoV-2 variants B.1.351 and B.1.1.248: Escape from therapeutic antibodies and antibodies induced by infection and vaccination
Markus Hoffmann, Prerna Arora, Rüdiger Groß, Alina Seidel, Bojan Hörnich, Alexander Hahn, Nadine Krüger, Luise Graichen, Heike Hofmann-Winkler, Amy Kempf, Martin Sebastian Winkler, Sebastian Schulz, Hans-Martin Jäck, Bernd Jahrsdörfer, Hubert Schrezenmeier, Martin Müller, Alexander Kleger, Jan Münch, Stefan Pöhlmann
bioRxiv 2021.02.11.430787; doi: https://doi.org/10.1101/2021.02.11.430787
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
SARS-CoV-2 variants B.1.351 and B.1.1.248: Escape from therapeutic antibodies and antibodies induced by infection and vaccination
Markus Hoffmann, Prerna Arora, Rüdiger Groß, Alina Seidel, Bojan Hörnich, Alexander Hahn, Nadine Krüger, Luise Graichen, Heike Hofmann-Winkler, Amy Kempf, Martin Sebastian Winkler, Sebastian Schulz, Hans-Martin Jäck, Bernd Jahrsdörfer, Hubert Schrezenmeier, Martin Müller, Alexander Kleger, Jan Münch, Stefan Pöhlmann
bioRxiv 2021.02.11.430787; doi: https://doi.org/10.1101/2021.02.11.430787

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Molecular Biology
Subject Areas
All Articles
  • Animal Behavior and Cognition (4114)
  • Biochemistry (8816)
  • Bioengineering (6519)
  • Bioinformatics (23465)
  • Biophysics (11792)
  • Cancer Biology (9211)
  • Cell Biology (13325)
  • Clinical Trials (138)
  • Developmental Biology (7439)
  • Ecology (11413)
  • Epidemiology (2066)
  • Evolutionary Biology (15155)
  • Genetics (10439)
  • Genomics (14045)
  • Immunology (9173)
  • Microbiology (22159)
  • Molecular Biology (8813)
  • Neuroscience (47577)
  • Paleontology (350)
  • Pathology (1429)
  • Pharmacology and Toxicology (2492)
  • Physiology (3731)
  • Plant Biology (8082)
  • Scientific Communication and Education (1437)
  • Synthetic Biology (2221)
  • Systems Biology (6039)
  • Zoology (1253)